Biocardia stock.

Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ... Nov 8, 2023 · BioCardia Reports First Quarter 2023 Business Highlights and Financial Results. BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications. BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023. BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol. The currently ongoing CardiAMP Heart Failure trial has completed enrollment and it is anticipated that the final data analyses will be reported in fourth quarter 2024.BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates Zacks - Wed Nov 9, 2022 . BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Nov 14, 2023 · SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

The estimated Net Worth of Peter Altman is at least 710 千$ dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over 32,786$ and over the last 6 years he sold BCDA stock worth over 0$. In addition, he makes 677,501$ as President、 Chief Executive Officer、 Director at BioCardia.

Full Company Report for BCDA. View BioCardia, Inc BCDA investment & stock information. Get the latest BioCardia, Inc BCDA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.View the latest BioCardia Inc. (BCDA) stock price, news, historical charts, analyst ratings and financial information from WSJ.

SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...The estimated Net Worth of Simon H Stertzer is at least 1.48 百万$ dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over 1,399,623$ and over the last 6 years he sold BCDA stock worth over 0$. In addition, he makes 76,250$ as Independent Chairman of the Board at BioCardia.BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange. Acute Myocardial Infarction Patients Treated Early With Cell Therapy …Looking to buy BCDAW Stock? View today's BCDAW stock price, trade commission-free, and discuss BioCardia Inc. - Warrants (26/07/2022) stock updates with the investor community.

Discover historical prices for ME stock on Yahoo Finance. View daily, weekly or monthly format back to when 23andMe Holding Co. stock was issued.

6 hari yang lalu ... GlobeNewswire. BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data ...

Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.BioCardia Inc. Stock Earnings. The value each BCDA share was expected to gain vs. the value that each BCDA share actually gained. BioCardia Inc. ( BCDA) reported Q2 2023 earnings per share (EPS) of -$0.17, missing estimates of -$0.16 by 7.23%. In the same quarter last year, BioCardia Inc. 's earnings per share (EPS) was -$0.14.GlobeNewswire News Room — BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules Funding Round • Nov 16, 2023 Artifact Lab raised $2,000,000 / Pre Seed from Cypher Capital and 4 other investorsThe estimated Net Worth of Simon H Stertzer is at least $461 Thousand dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $385,217 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.Nov 18, 2023 · BioCardia Stock Down 10.0 %. NASDAQ BCDA opened at $0.72 on Tuesday. The stock has a market capitalization of $15.59 million, a P/E ratio of -1.16 and a beta of 1.29. BioCardia has a 52-week low of $0.36 and a 52-week high of $2.92. The firm has a 50-day moving average price of $0.44 and a 200 day moving average price of $1.26.

BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and …SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...Related: H.C. Wainwright Sees Over 400% Upside For BioCardia Stock. The therapy incorporates a pre-procedural screening assay to identify patients who may be likely responders, ...SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...BioCardia Inc (BCDA) stock is trading at $0.88 as of 9:36 AM on Thursday, Nov 16, a loss of -$0.07, or -6.91% from the previous closing price of $0.95. The stock has traded between $0.84 and $0.89 so far today. Volume today is light. So far 173,359 shares have traded compared to average volume of 4,872,239 shares.

Dec 1, 2023 · Earnings for BioCardia are expected to decrease in the coming year, from ($0.54) to ($0.56) per share. BioCardia has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read More.

The FDA approved BioCardia Inc's (NASDAQ: BCDA) Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for ischemic heart failure. The currently ongoing CardiAMP ...Mr. Fernandez BCDA stock SEC Form 4 insiders trading. Fernando has made over 1 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 14,277 units of BCDA stock worth $5,711 on 13 January 2018.14,277 units of BCDA stock worth $5,711 on 13 January 2018.Dec 15, 2022 · The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ... BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmo...BioCardia Inc (BCDA) stock is trading at $2.16 as of 10:19 AM on Friday, Jun 9, an increase of $0.04, or 1.89% from the previous closing price of $2.12. The stock has traded between $2.15 and $2.18 so far today. Volume today is light. So far 5,707 shares have traded compared to average volume of 41,498 shares.6 hari yang lalu ... BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of ...2023 BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023 24 Jul 2023 BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

The Wall Street analyst predicted. that Biocardia's share price could reach $4.00 by Nov 14, 2024. The average Biocardia stock price prediction forecasts a potential upside of 495.24% from the current BCDA share price of $0.67.

A new COVID variant, HV.1, is now dominant. These are its most common symptoms. Deer hunting is dying. That should worry you even if you don't hunt. The FDA approved BioCardia Inc's (NASDAQ: BCDA ...

Over the past 3 months, 4 analysts have published their opinion on BioCardia (NASDAQ:BCDA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ...Nov 29, 2023 · See the latest BioCardia Inc stock price (BCDA:XNAS), related news, valuation, dividends and more to help you make your investing decisions. The BioCardia stock prediction for 2025 is currently $ 139.62, assuming that BioCardia shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 20,667.78% increase in the BCDA stock price. Nov 14, 2023 · SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure. BioCardia has received a go-ahead from the FDA for a first-in-human trial of a second version of its stem cell implants designed to help rescue patients from heart failure. The green light clears ...BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart F. Find the latest BioCardia, Inc. (BCDA) stock quote, …Mr. McClung BCDA stock SEC Form 4 insiders trading. David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.1,600 units of BCDA stock worth $4,096 on 5 November 2018.Nov 29, 2023 · A high-level overview of BioCardia, Inc. (BCDA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...The estimated Net Worth of Richard M Krasno is at least $385 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $114,800 and over the last 17 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.The estimated Net Worth of Peter Altman is at least $849 Tausend dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $171,654 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer und Director at BioCardia.Nov 17, 2023 · Source. Headline. Genocea Biosciences (NASDAQ:GNCAQ) vs. BioCardia (NASDAQ:BCDA) Financial Analysis. americanbankingnews.com - November 17 at 1:30 AM. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. finance.yahoo.com - November 16 at 3:00 PM. Instagram:https://instagram. financial advisors fort waynedangerous trends on social mediaplatinum asset managementschwab bond index fund BioCardia Inc (BCDA) stock is unmoved 0% while the S&P 500 is higher by 1.44% as of 4:00 PM on Monday, Nov 13. BCDA is unmoved $0.00 from the previous closing price of $0.40 on volume of 39,170,298 shares. Over the past year the S&P 500 has gained 13.09% while BCDA has fallen -78.61%. BCDA lost -$0.63 per share the over the last 12 months.BioCardia, Inc. Stock price Equities BCDA US09060U5074 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar Company Financials … invest with elon muskschwab money market rate Richard has made over 43 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BCDA stock worth $14,600 on 17 June 2019.Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple. wise. Select a currency. USD. NASDAQ: Biocardia Inc ( BCDA) = 0.71 USD. Provided by Alpha Vantage. ltry stocktwits Find the latest BioCardia, Inc. (6JU.F) stock quote, history, news and other vital information to help you with your stock trading and investing.Convert BioCardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: BioCardia Inc (BCDAW) = 0.06 USD. Provided by Alpha Vantage. BioCardia Inc stock (BCDAW) in USD. 1 BCDAW = 0.06 USD. 1 month.